DOCSLIB.ORG

WLI/100 11 Novembre 2011 ACCORD DE MARRAKECH INSTITUANT L

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
WLI/100 11 Novembre 2011 ACCORD DE MARRAKECH INSTITUANT L WORLD TRADE ORGANIZATION ORGANISATION MONDIALE DU COMMERCE ORGANIZACIÓN MUNDIAL DEL COMERCIO Référence: WLI/100 11 novembre 2011 ACCORD DE MARRAKECH INSTITUANT L'ORGANISATION MONDIALE DU COMMERCE FAIT À MARRAKECH LE 15 AVRIL 1994 ACCORD GÉNÉRAL SUR LES TARIFS DOUANIERS ET LE COMMERCE DE 1994 CERTIFICATION DE MODIFICATIONS ET DE RECTIFICATIONS LISTE XXXVIII – JAPON ENVOI DE COPIE CERTIFIÉE CONFORME J'ai l'honneur de vous faire parvenir ci-joint une copie certifiée conforme de la Certification des modifications et des rectifications apportées à la Liste XXXVIII – Japon, qui ont pris effet le 4 novembre 2011. Pascal Lamy Directeur général 11-5834 WT/Let/835 Centre William Rappard Rue de Lausanne 154 Case postale CH - 1211 Genève 21 Téléphone: (+41 22) 739 51 11 Fax: (+41 22) 731 42 06 Internet: http://www.wto.org LISTES DE CONCESSIONS TARIFAIRES ANNEXÉES À L'ACCORD GENERAL SUR LES TARIFS DOUANIERS ET LE COMMERCE DE 1994 CERTIFICATION DE MODIFICATIONS ET DE RECTIFICATIONS LISTE XXXVIII – JAPON CONSIDÉRANT que les PARTIES CONTRACTANTES à l'Accord général sur les tarifs douaniers et le commerce de 1947 ont adopté, le 26 mars 1980, une Décision sur les procédures de modification et de rectification des listes de concessions tarifaires (IBDD, S27/26); CONSIDÉRANT que, conformément aux dispositions de la Décision susmentionnée, le projet contenant les modifications et les rectifications concernant la Liste XXXVIII – Japon a été communiqué à tous les Membres sous couvert du document G/MA/TAR/RS/291 et G/MA/TAR/RS/291/Corr.1; IL EST CERTIFIÉ PAR LA PRÉSENTE que les modifications et les rectifications concernant la Liste XXXVIII – Japon sont établies conformément à la Décision susmentionnée. Les modifications et les rectifications apportées en annexe à la liste prennent effet conformément à la notification que le gouvernement japonais adresse à cette fin au Directeur général de l'Organisation mondiale du commerce lorsque les procédures internes du Japon ont été achevées. La présente certification est déposée auprès du Directeur général de l'Organisation mondiale du commerce, qui en remettra dans les moindres délais une copie certifiée conforme à chaque Membre de l'Organisation mondiale du commerce. Elle sera enregistrée conformément aux dispositions de l'article 102 de la Charte des Nations Unies. FAIT à Genève le quatre novembre deux mille onze. Copie certifiée conforme: Directeur général MODIFICATIONS AND RECTIFICATIONS TO SCHEDULE XXXVIII – JAPAN Schedule XXXVIII – Japan Page 5 WT/Let/835 SCHEDULE XXXVIII – Japan 4 November 2011 Schedule XXXVIII – Japan Page 6 WT/Let/835 PART I MOST-FAVOURED-NATION TARIFF SECTION II Other Products Mark the tariff item number 2843.29, 2910.20, 2921.51 with a letter “P” Schedule XXXVIII – Japan Page 7 WT/Let/835 Attachment to SCHEDULE XXXVIII – JAPAN Replace “Annexes IA, IB, IC and ID” in category (3) by “Annexes IA, IB, IC, ID and IE”. Replace “Annexes IA, IB, IC and ID” in category (4) by “Annexes IA, IB, IC, ID and IE”, and “Annex II” by “Annexes IIA and IIB”. Replace “Annexes IVA, IVB, IVC and IVD” in category (6) by “Annexes IVA, IVB, IVC, IVD and IVE”. Schedule XXXVIII – Japan Page 8 WT/Let/835 Insert the following Annex after Annex ID ANNEX IE Designated Pharmaceutical Active Ingredients (Additions by the fourth review) HS Subheading Description HS Subheading Description 2842.90 fermagate 2924.29 firategrast 2843.90 padeliporfin 2924.29 gabapentin enacarbil 2844.40 iodofiltic acid (123I) 2924.29 incyclinide 2904.10 eprodisate 2924.29 indantadol 2906.19 elocalcitol 2924.29 levomilnacipran 2909.30 terameprocol 2924.29 lisdexamfetamine 2916.19 peretinoin 2924.29 milveterol 2916.39 tarenflurbil 2924.29 ombrabulin 2918.19 bevirimat 2924.29 senicapoc 2919.00 fospropofol 2925.19 pomalidomide 2920.90 naproxcinod 2928.00 olesoxime 2921.19 tramiprosate 2928.00 sivifene 2922.19 afimoxifene 2928.00 tecovirimat 2922.19 ronacaleret 2928.00 tosedostat 2922.22 faxeladol 2928.00 vorinostat 2922.50 amibegron 2929.90 palifosfamide 2922.50 cinaciguat 2930.90 apremilast 2922.50 fasobegron 2930.90 camobucol 2923.10 choline fenofibrate 2930.90 dalcetrapib 2924.29 arbaclofen placarbil 2930.90 darinaparsin 2924.29 bedoradrine 2930.90 elesclomol 2924.29 carisbamate 2930.90 elsibucol 2924.29 emricasan 2930.90 ezatiostat 2924.29 eprotirome 2930.90 metenkefalin Schedule XXXVIII – Japan Page 9 WT/Let/835 HS Subheading Description HS Subheading Description 2930.90 monepantel 2933.39 befiradol 2930.90 odanacatib 2933.39 betrixaban 2930.90 salirasib 2933.39 daporinad 2930.90 succinobucol 2933.39 entinostat 2930.90 tipelukast 2933.39 goxalapladib 2931.00 amsilarotene 2933.39 imisopasem manganese 2932.19 eribulin 2933.39 levamlodipine 2932.19 pafuramidine 2933.39 levonadifloxacin 2932.29 omtriptolide 2933.39 migalastat 2932.99 arterolane 2933.39 motesanib 2932.99 cabazitaxel 2933.39 parogrelil 2932.99 celivarone 2933.39 pexacerfont 2932.99 dapagliflozin 2933.39 pimavanserin 2932.99 dexnebivolol 2933.39 pitolisant 2932.99 larotaxel 2933.39 rosonabant 2932.99 levonebivolol 2933.39 taranabant 2932.99 mifamurtide 2933.39 tropantiol 2932.99 vadimezan 2933.39 vapitadine 2933.19 eltrombopag 2933.39 volinaserin 2933.19 niraxostat 2933.49 almorexant 2933.19 palovarotene 2933.49 balamapimod 2933.19 totrombopag 2933.49 besifloxacin 2933.29 catramilast 2933.49 elvitegravir 2933.29 demiditraz 2933.49 ferroquine 2933.29 dulanermin 2933.49 intiquinatine 2933.29 lixisenatide 2933.49 nemonoxacin 2933.29 rolipoltide 2933.49 neratinib 2933.29 velafermin 2933.49 ozenoxacin 2933.39 alcaftadine 2933.49 rilapladib 2933.39 amifampridine 2933.49 tezampanel 2933.39 anamorelin 2933.49 veliflapon 2933.39 axitinib 2933.59 aderbasib Schedule XXXVIII – Japan Page 10 WT/Let/835 HS Subheading Description HS Subheading Description 2933.59 adipiplon 2933.79 mimopezil 2933.59 alogliptin 2933.79 orvepitant 2933.59 bafetinib 2933.79 pamapimod 2933.59 bosutinib 2933.79 paquinimod 2933.59 cariprazine 2933.79 perampanel 2933.59 casopitant 2933.79 rolapitant 2933.59 cediranib 2933.79 semagacestat 2933.59 cevipabulin 2933.79 voclosporin 2933.59 danusertib 2933.99 aleplasinin 2933.59 darapladib 2933.99 boceprevir 2933.59 dutacatib 2933.99 brivanib alaninate 2933.59 fimasartan 2933.99 denagliptin 2933.59 folitixorin 2933.99 denibulin 2933.59 linagliptin 2933.99 diaplasinin 2933.59 macitentan 2933.99 disitertide 2933.59 nilotinib 2933.99 epetirimod 2933.59 olaparib 2933.99 favipiravir 2933.59 otenabant 2933.99 flovagatran 2933.59 riociguat 2933.99 golotimod 2933.59 sitagliptin 2933.99 larazotide 2933.59 sotrastaurin 2933.99 laropiprant 2933.59 talmapimod 2933.99 lorcaserin 2933.59 talotrexin 2933.99 melogliptin 2933.59 ticagrelor 2933.99 obatoclax 2933.59 vicriviroc 2933.99 panobinostat 2933.69 imeglimin 2933.99 piragliatin 2933.79 aplaviroc 2933.99 pyronaridine 2933.79 bremelanotide 2933.99 rabeximod 2933.79 carmegliptin 2933.99 rotigaptide 2933.79 dovitinib 2933.99 rusalatide 2933.79 eribaxaban 2933.99 sofigatran 2933.79 ilepatril 2933.99 sotirimod Schedule XXXVIII – Japan Page 11 WT/Let/835 HS Subheading Description HS Subheading Description 2933.99 telaprevir 2934.99 bevasiranib 2933.99 tigapotide 2934.99 capeserod 2933.99 tiplasinin 2934.99 carfilzomib 2933.99 vabicaserin 2934.99 cenersen 2933.99 vernakalant 2934.99 conestat alfa 2934.10 capadenoson 2934.99 custirsen 2934.10 dasatinib 2934.99 derquantel 2934.10 inolitazone 2934.99 dexelvucitabine 2934.10 isavuconazole 2934.99 dilopetine 2934.10 isavuconazonium chloride2934.99 edoxaban 2934.10 lobeglitazone 2934.99 elacytarabine 2934.10 managlinat dialanetil 2934.99 esreboxetine 2934.10 masitinib 2934.99 fosalvudine tidoxil 2934.10 mirabegron 2934.99 fosaprepitant 2934.10 rosabulin 2934.99 ibodutant 2934.10 sodelglitazar 2934.99 idrabiotaparinux sodium 2934.10 teneligliptin 2934.99 imepitoin 2934.20 bentamapimod 2934.99 inakalant 2934.20 talarozole 2934.99 lancovutide 2934.99 aclidinium bromide 2934.99 lapaquistat 2934.99 adoprazine 2934.99 lensiprazine 2934.99 agatolimod 2934.99 lificiguat 2934.99 aleglitazar 2934.99 litenimod 2934.99 amolimogene bepiplasmid 2934.99 mipomersen 2934.99 anacetrapib 2934.99 nepidermin 2934.99 apadenoson 2934.99 omacetaxine mepesuccinate 2934.99 apilimod 2934.99 pardoprunox 2934.99 apricitabine 2934.99 pramiconazole 2934.99 azilsartan 2934.99 preladenant 2934.99 azilsartan medoxomil 2934.99 prinaberel 2934.99 bederocin 2934.99 quarfloxin 2934.99 beperminogene perplasmid 2934.99 radezolid Schedule XXXVIII – Japan Page 12 WT/Let/835 HS Subheading Description HS Subheading Description 2934.99 radiprodil 2935.00 nesbuvir 2934.99 raltegravir 2935.00 oglemilast 2934.99 regrelor 2935.00 pazopanib 2934.99 retosiban 2935.00 relacatib 2934.99 ridaforolimus 2935.00 resatorvid 2934.99 romidepsin 2935.00 tasisulam 2934.99 ropidoxuridine 2935.00 zibotentan 2934.99 sapacitabine 2940.00 ferric carboxymaltose 2934.99 saracatinib 2940.00 remogliflozin etabonate 2934.99 simotaxel 2940.00 sergliflozin etabonate 2934.99 taribavirin 3507.90 bucelipase alfa 2934.99 telatinib 3507.90 pegloticase 2934.99 trabedersen 3507.90 velaglucerase alfa 2934.99 trelanserin 3911.90 azoximer bromide 2934.99 velimogene aliplasmid 2934.99 viquidacin 2934.99 votucalis 2934.99 zotarolimus 2935.00 apricoxib 2935.00 begacestat 2935.00 belinostat 2935.00 brecanavir 2935.00 cevoglitazar 2935.00 drinabant 2935.00 giripladib 2935.00 ibipinabant 2935.00 laromustine 2935.00 lodenafil carbonate 2935.00 masilukast 2935.00 mavacoxib 2935.00 mirodenafil 2935.00 nelivaptan Schedule XXXVIII – Japan Page 13 WT/Let/835 Renumber Annex II as
Load more

Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2005/0065361A1 Deshmukh Et Al
    US 2005OO65361A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2005/0065361A1 Deshmukh et al. (43) Pub. Date: Mar. 24, 2005 (54) PROCESS FOR PREPARING ALKYLARYL (22) Filed: Sep. 22, 2003 CHLOROFORMATES Publication Classification (76) Inventors: Abdul Rakeeb Abdul Subhan Deshmukh, Maharashtra (IN); Vikas (51) Int. Cl." ........................... C07C 69/74; C07C 69/96 Kalyanrao Gumaste, Maharashtra (IN) (52) U.S. Cl. .............................................................. 558/280 Correspondence Address: (57) ABSTRACT NIXON & VANDERHYE, PC The present invention discloses an improved method for the 1100 N GLEBE ROAD preparation of alky/aryl chloroformates directly from alco 8TH FLOOR hols and triphosgene. This method is simple, mild and ARLINGTON, VA 22201-4714 (US) efficient avoids use of hazardous phosgene. It can be used for the preparation of various aryl as well as alkyl chlorofor (21) Appl. No.: 10/665,410 mates in excellent yields. US 2005/0065361 A1 Mar. 24, 2005 PROCESS FOR PREPARING ALKYLARYL Maligres, K. C. Nicolau, W. Wrasidio Bioorg. Med. Chem. CHLOROFORMATES Lett. 1993, 3, 1051. (c) D. C. Horwell, J. Hughes, J. Hunter, M. C. Pritchard, R. S. Richardson, E. Roberts, G. N. FIELD OF THE INVENTION Woodruff J. Med. Chem., 1991, 34, 404 and tertiary amines as base H. Eckert, B. Forster, Angew. Chem. Int. Ed. Engl., 0001. The present invention relates to a process for 1987,26,894). Hydroquinone is also used in the preparation preparing alkyl/aryl chloroformates. More particularly, the of chloroformates from triphosgene G. Van den Mooter, C. present invention relates to a process for preparing com Samyn, R. Kinget Int. J. Pharm., 1993, 97, 133).
    [Show full text]
  • Modifications to the Harmonized Tariff Schedule of the United States to Implement Changes to the Pharmaceutical Appendix
    United States International Trade Commission Modifications to the Harmonized Tariff Schedule of the United States to Implement Changes to the Pharmaceutical Appendix USITC Publication 4208 December 2010 U.S. International Trade Commission COMMISSIONERS Deanna Tanner Okun, Chairman Irving A. Williamson, Vice Chairman Charlotte R. Lane Daniel R. Pearson Shara L. Aranoff Dean A. Pinkert Address all communications to Secretary to the Commission United States International Trade Commission Washington, DC 20436 U.S. International Trade Commission Washington, DC 20436 www.usitc.gov Modifications to the Harmonized Tariff Schedule of the United States to Implement Changes to the Pharmaceutical Appendix Publication 4208 December 2010 (This page is intentionally blank) Pursuant to the letter of request from the United States Trade Representative of December 15, 2010, set forth at the end of this publication, and pursuant to section 1207(a) of the Omnibus Trade and Competitiveness Act, the United States International Trade Commission is publishing the following modifications to the Harmonized Tariff Schedule of the United States (HTS) to implement changes to the Pharmaceutical Appendix, effective on January 1, 2011. Table 1 International Nonproprietary Name (INN) products proposed for addition to the Pharmaceutical Appendix to the Harmonized Tariff Schedule INN CAS Number Abagovomab 792921-10-9 Aclidinium Bromide 320345-99-1 Aderbasib 791828-58-5 Adipiplon 840486-93-3 Adoprazine 222551-17-9 Afimoxifene 68392-35-8 Aflibercept 862111-32-8 Agatolimod
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • Potential Cannabis Antagonists for Marijuana Intoxication
    Central Journal of Pharmacology & Clinical Toxicology Bringing Excellence in Open Access Review Article *Corresponding author Matthew Kagan, M.D., Cedars-Sinai Medical Center, 8730 Alden Drive, Los Angeles, CA 90048, USA, Tel: 310- Potential Cannabis Antagonists 423-3465; Fax: 310.423.8397; Email: Matthew.Kagan@ cshs.org Submitted: 11 October 2018 for Marijuana Intoxication Accepted: 23 October 2018 William W. Ishak, Jonathan Dang, Steven Clevenger, Shaina Published: 25 October 2018 Ganjian, Samantha Cohen, and Matthew Kagan* ISSN: 2333-7079 Cedars-Sinai Medical Center, USA Copyright © 2018 Kagan et al. Abstract OPEN ACCESS Keywords Cannabis use is on the rise leading to the need to address the medical, psychosocial, • Cannabis and economic effects of cannabis intoxication. While effective agents have not yet been • Cannabinoids implemented for the treatment of acute marijuana intoxication, a number of compounds • Antagonist continue to hold promise for treatment of cannabinoid intoxication. Potential therapeutic • Marijuana agents are reviewed with advantages and side effects. Three agents appear to merit • Intoxication further inquiry; most notably Cannabidiol with some evidence of antipsychotic activity • THC and in addition Virodhamine and Tetrahydrocannabivarin with a similar mixed receptor profile. Given the results of this research, continued development of agents acting on cannabinoid receptors with and without peripheral selectivity may lead to an effective treatment for acute cannabinoid intoxication. Much work still remains to develop strategies that will interrupt and reverse the effects of acute marijuana intoxication. ABBREVIATIONS Therapeutic uses of cannabis include chronic pain, loss of appetite, spasticity, and chemotherapy-associated nausea and CBD: Cannabidiol; CBG: Cannabigerol; THCV: vomiting [8]. Recreational cannabis use is on the rise with more Tetrahydrocannabivarin; THC: Tetrahydrocannabinol states approving its use and it is viewed as no different from INTRODUCTION recreational use of alcohol or tobacco [9].
    [Show full text]
  • Chapter 6 Industrial Applications of Multicomponent Reactions (Mcrs)
    University of Groningen Innovative multicomponent reactions and their use in medicinal chemistry Zarganes Tzitzikas, Tryfon IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below. Document Version Publisher's PDF, also known as Version of record Publication date: 2017 Link to publication in University of Groningen/UMCG research database Citation for published version (APA): Zarganes Tzitzikas, T. (2017). Innovative multicomponent reactions and their use in medicinal chemistry. University of Groningen. Copyright Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons). Take-down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum. Download date: 24-09-2021 CHAPTER 6 INDUSTRIAL APPLICATIONS OF MULTICOMPONENT REACTIONS (MCRS) Chapter contained in the Rodriguez-Bonne book Stereoselectve Multple Bond-Forming Transformatons in Organic Synthesis 2015 by John Wiley & Sons, Inc. Tryfon Zarganes – Tzitzikas, Ahmad Yazbak, Alexander Dömling Chapter 6 INTRODUCTION Multcomponent reactons (MCRs) can be defned as processes in which three or more reactants introduced simultaneously are combined through covalent bonds to form a single product, regardless of the mechanisms and protocols involved.[1] Many basic MCRs are name reactons, for example, Ugi,[2] Passerini,[3] van Leusen,[4] Strecker,[5] Hantzsch,[6] Biginelli,[7] or one of their many variatons.
    [Show full text]
  • Novel Approaches in Clinical Development of Cannabinoid Drugs
    Novel approaches in clinical development of cannabinoid drugs Linda Klumpers novel approaches in clinical development of cannabinoid drugs Novel approaches in clinical development of cannabinoid drugs proefschrift ter verkrijging van de graad van Doctor aan de Universiteit Leiden, op gezag van de Rector Magnificus prof. mr. C.J.J.M. Stolker, volgens besluit van het College voor Promoties, te verdedigen op dinsdag 21 januari 2014, klokke 16:15 uur door Linda Elvira Klumpers, geboren te Rotterdam in 1980 Promotiecommissie chapter i 7 Introduction to the endocannabinoid system as a target for drug development promotores Prof. dr. J.M.A. van Gerven chapter ii 49 Professor of Clinical Neuropsychopharmacology, Leiden University Medical Center Novel ∆9-tetrahydrocannabinol formulation Namisol® has bene- and Centre for Human Drug Research ficial pharmacokinetics and promising pharmacodynamic effects Prof. dr. A.F. Cohen Professor of Clinical Pharmacology, Leiden University Medical Center and Centre chapter iii 79 for Human Drug Research Manipulating brain connectivity with ∆9-tetrahydrocannabinol: a pharmacological resting state fmri study overige leden chapter iv 115 Prof. dr. P.H. van der Graaf Surinabant, a selective cb¡ antagonist, inhibits thc-induced Professor of Bio-pharmaceutical Sciences, Leiden University central nervous system and heart rate effects in humans Dr. J.T. Tamsma Internist and Medical Director of the Leiden University Medical Center chapter v 145 Prof. dr. R.F. Witkamp Peripheral selectivity of the novel cannabinoid receptor
    [Show full text]
  • The Preparation of Certain Organic Chloroformates and Carbonates
    Brigham Young University BYU ScholarsArchive Theses and Dissertations 1947-04-01 The preparation of certain organic chloroformates and carbonates Robert E. Brailsford Brigham Young University - Provo Follow this and additional works at: https://scholarsarchive.byu.edu/etd BYU ScholarsArchive Citation Brailsford, Robert E., "The preparation of certain organic chloroformates and carbonates" (1947). Theses and Dissertations. 8175. https://scholarsarchive.byu.edu/etd/8175 This Thesis is brought to you for free and open access by BYU ScholarsArchive. It has been accepted for inclusion in Theses and Dissertations by an authorized administrator of BYU ScholarsArchive. For more information, please contact [email protected], [email protected]. THE PREPARATI OH OF CERTAI N 0RG.1NIC CHLOROFORJ.'\Ll.TES AND CARBON T Thesis ubmitted to the Department of Chemistry Brigham Young University ~ .. ... "') .~ . ~ . "'). ... .. .. .. .. , ... .. ... : : ....: . ..-. ~ ..·.: : ..: ...• : ·.. ~ . : ,.. .~ : :. : ·: : ··.... ; ~ : ·. : : .: . : . : : : ••• .... •." •,.r_·: -••• ~ .... In Parti a l Fulfillment of the Re~uirements for the Degree Master of cienoe 147143 by Robert E. Brailsford .tipril 1947 This Thesis by Robert E. Brailsford is accepted in its present farm by the Department of Chemistry of Brigham Young University as satisfying the ·rhesis requirement for the degree of Master of Science. PREFACE flhile working for the Hooker Electrochemical Company of Niagara Falls , New York , from April 3 , 1943 , to January 30 , 1946 , the writer became interested in organic chloroformates and. carbonates , an interest instigated by requests from B. F . Goodrich Company for a number of samples . fter returning to Brigham Young University that preliminary interest was revived and the experi - mental work of this thesis was performed. under the direction of Dr . Charles ' . :Maw and Professor Joseph K.
    [Show full text]
  • Carbonate and Benzyl Benzotriazol-L-Yl Carbonate. Now
    70 Bull. Korean Chem. Soc., Vol. 7, No. 1, 1986 Sunggak Kim and Heung Chang t-Butyl Benzotriazol-l-yl Carbonate and Benzyl Benzotriazol-l-yl Carbonate. Now Reactive Amino Protective Reagents for t-Butoxy carbonylation and Benzyloxycarbonylation of Amines and Amino Acids Sunggak Kim* and Heung Chang Department of Chemistry, Korea Advanced Institute of Science and Technology, Seoul 131, Received September24,1985 New amino protective reagents, /-butyl benzotriazol-l-yl carbonate and benzyl benzotriazol-l-yl carbonate, for t~ butoxycarbonylation and benzyloxycarbonylation of amines and amino acids have been developed. f-Butyl benzotriazol-1 -yl carbonate reacts rapidly and cleanly with various amines and amino acids to afford N-Boc amines and N-Boc amino acids in high yields and benzyl benzotriazol-l-yl carbonate is also found to be very effective in the benzyloxycarbonylation of amino acids. Introduction a solution of an equimolar amount of 1-hydroxybenzotriazole and pyridine in methylene chloride to the solution of an ex­ The Z-butoxycarbonyl (Boc) group is one of the most im­ cess amount of phosgene in toluene under cooling portant amino protective groups along with benzyloxycarbonyl (-20~ 一 10°C). The resulting product was relatively unstable (Cbz) group in peptide synthesis.1 Since /-butyl chloroformate and was mainly decomposed to 1-hydroxybenzotriazole dur­ is only fairly stable above 10°C,2 it is difficult to is이 ate t- ing workup with cold water. Thus； benzotriazol-l-yl chlorofor­ butyl chloroformate as a pure form in high yields. Thus, con­ mate was used in a crude form. BBC could be prepared readily siderable efforts have been devoted to the development of a by the reaction of benzotriazol-l-yl chloroformate with variety of useful and reliable reagents for the preparation of equimolar amounts of f나 mtyl alcohol and pyridine in N-Boc amino acids during last 30 years.1 methylene chloride at room temperature for 2 h (eq.
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • Cannabinoid Receptor Cannabinoid Receptor
    Cannabinoid Receptor Cannabinoid Receptor Cannabinoid receptors are currently classified into three groups: central (CB1), peripheral (CB2) and GPR55, all of which are G-protein-coupled. CB1 receptors are primarily located at central and peripheral nerve terminals. CB2 receptors are predominantly expressed in non-neuronal tissues, particularly immune cells, where they modulate cytokine release and cell migration. Recent reports have suggested that CB2 receptors may also be expressed in the CNS. GPR55 receptors are non-CB1/CB2 receptors that exhibit affinity for endogenous, plant and synthetic cannabinoids. Endogenous ligands for cannabinoid receptors have been discovered, including anandamide and 2-arachidonylglycerol. www.MedChemExpress.com 1 Cannabinoid Receptor Antagonists, Agonists, Inhibitors, Modulators & Activators (S)-MRI-1867 (±)-Ibipinabant Cat. No.: HY-141411A ((±)-SLV319; (±)-BMS-646256) Cat. No.: HY-14791A (S)-MRI-1867 is a peripherally restricted, orally (±)-Ibipinabant ((±)-SLV319) is the racemate of bioavailable dual cannabinoid CB1 receptor and SLV319. (±)-Ibipinabant ((±)-SLV319) is a potent inducible NOS (iNOS) antagonist. (S)-MRI-1867 and selective cannabinoid-1 (CB-1) receptor ameliorates obesity-induced chronic kidney disease antagonist with an IC50 of 22 nM. (CKD). Purity: >98% Purity: 99.93% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg 2-Arachidonoylglycerol 2-Palmitoylglycerol Cat. No.: HY-W011051 (2-Palm-Gl) Cat. No.: HY-W013788 2-Arachidonoylglycerol is a second endogenous 2-Palmitoylglycerol (2-Palm-Gl), an congener of cannabinoid ligand in the central nervous system. 2-arachidonoylglycerol (2-AG), is a modest cannabinoid receptor CB1 agonist. 2-Palmitoylglycerol also may be an endogenous ligand for GPR119.
    [Show full text]
  • Benzyl Chloroformate (CHLOROFORMIC ACID, BENZYL ESTER)
    Rev B Benzyl Chloroformate (CHLOROFORMIC ACID, BENZYL ESTER) C8H7O2Cl Molecular Weight = 170.6 CAS# 501‐53‐1 SPECIFICATIONS Assay: 98.% min. Color (APHA): 50 max. Benzyl Alcohol: 0.1% max. Hydrogen Chloride: 0.1% max. Benzyl Chloride: 1.5% max. Phosgene: 0.1% max. Dibenzyl Carbonate: 0.5% max. Iron: 1.5 PPM max. PHYSICAL PROPERTIES Appearance: Clear liquid free of visible contaminants BP: Decomposes at elevated temperature Odor: Pungent Density: 1.195 ‐1.22 MP/Range: ‐30°C Flash Point: 126°C NOTICE: The technical information and suggestions for use made herein are based on VanDeMark’s research and experience and are believed to be reliable, but such information and suggestions do not constitute a warranty, and no patent liability can be assumed. This publication is not to be taken as a license to operate under or infringe on any patents. Since VanDeMark has no control over the conditions under which the product is transported, stored, handled, used or applied, buyer must determine for himself by preliminary tests or otherwise, the suitability of the product for his purposes. VanDeMark’s liability on any basis is limited to the price of the product used. The information in this bulletin supersedes all previously issued bulletins on the subject matter covered. VanDeMark Benzyl Chloroformate APPLICATIONS SPILLS AND DISPOSAL Benzyl Chloroformate is a reactive chemical intermediate Use personal protective equipment (see MSDS). used in the synthesis of pharmaceutical and agrochemical Evacuate personnel to safe areas. Dike far ahead of products. It is used as a reagent in peptide synthesis to liquid spill for later disposal.
    [Show full text]
  • Synthesis, Utility and Medicinal Importance of 1,2- & 1,4
    RSC Advances REVIEW View Article Online View Journal | View Issue Synthesis, utility and medicinal importance of 1,2- & 1,4-dihydropyridines Cite this: RSC Adv.,2017,7, 2682 Vivek K. Sharmaa and Sunil K. Singh*b Dihydropyridine (DHP) is among the most beneficial scaffolds that have revolutionised pharmaceutical research with unprecedented biological properties. Over the years, metamorphosis of easily accessible 1,2- and 1,4-dihydropyridine (1,4-DHP) intermediates by synthetic chemists has generated several drug molecules and natural products such as alkaloids. The 1,4-dihydropyridine (1,4-DHP) moiety itself is the main fulcrum of several approved drugs. The present review aims to collate the literature of 1,2- and the 1,4-DHPs relevant to synthetic and medicinal chemists. We will describe various Received 6th October 2016 methodologies that have been used for the synthesis of this class of compounds, including the Accepted 14th November 2016 strategies which can furnish enantiopure DHPs, either by asymmetric synthesis or by chiral resolution. DOI: 10.1039/c6ra24823c We will also elaborate the significance of DHPs towards the synthesis of natural products of medicinal www.rsc.org/advances merit. Creative Commons Attribution 3.0 Unported Licence. 1. Introduction oxidation–reduction reactions, has made the 1,4-DHP core even more lucrative. Perhaps less studied in the past, the potential of Arthur Hantzsch added one of the most valuable scaffolds to the 1,2-dihydropyridines has recently been explored as a critical toolbox of medicinal chemists, reporting the synthesis of scaffold for the synthesis of alkaloids and other drugs. 1,2-DHPs dihydropyridine (DHP) in 1882.
    [Show full text]